Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Interventional × GIST × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 981 Carcinoma, Non-Small-Cell Lung 618 Neoplasms 484 Prostatic Neoplasms 442 Colorectal Neoplasms 379 Multiple Myeloma 292 Lung Neoplasms 267 Neoplasm Metastasis 258 Leukemia, Myeloid, Acute 233 Carcinoma, Hepatocellular 223 Stomach Neoplasms 220 Ovarian Neoplasms 193 Rectal Neoplasms 185 Lymphoma, Follicular 176 Lymphoma 176 Colonic Neoplasms 175 Leukemia 164 Uterine Cervical Neoplasms 157 Pancreatic Neoplasms 155 Head and Neck Neoplasms 150 Lymphoma, Non-Hodgkin 148 Recurrence 144 Lymphoma, Large B-Cell, Diffuse 142 Leukemia, Lymphocytic, Chronic, B-Cell 141 Precursor Cell Lymphoblastic Leukemia-Lymphoma 139 Melanoma 137 Brain Neoplasms 126 Urinary Bladder Neoplasms 124 Pain 124 Squamous Cell Carcinoma of Head and Neck 123

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡